Pelias, which contains the active substance ranolazine, is a medication associated with the therapeutic area of chronic angina, or persistent chest pain. Ranolazine is indicated for the treatment of chronic angina and is authorized for use alongside other established heart therapies, which may include beta-blockers, nitrates, and calcium channel blockers.

Pelias is studied for its role in potentially decreasing the frequency of angina episodes and may help support exercise capability. This medicine is intended to support the relief of symptoms related to coronary artery disease, which occurs when the heart muscle may not receive sufficient oxygen-rich blood, causing discomfort or pressure in the chest.

“This medication is indicated for use in the management of chronic, ongoing symptoms of stable angina and may contribute to fewer related episodes.”

Quick Fact: Therapeutic Role in Stable Angina Chest Pain

The primary therapeutic application centers on the management of chronic, persistent angina symptoms.

Regulatory References

1. NIH DailyMed drug label

Populations Who Must Not Use Pelias

Pelias (ranolazine) is subject to strict eligibility rules documented in official regulatory labeling. Use is contraindicated and must be avoided in several defined patient populations.

• Organ Function: Patients with liver cirrhosis or severe renal impairment (creatinine clearance less than 30 mL/min) are absolutely excluded from use.
• Concomitant Medication: Pelias is contraindicated for individuals who are concurrently taking either strong CYP3A inhibitors (such as ketoconazole or clarithromycin) or strong CYP3A inducers (such as rifampin or St. John's wort).

Conditional Use and Age Restrictions

Use is established only in adults with chronic stable angina. Safety and efficacy have not been established in children and adolescents under 18 years of age, and use is not recommended for this group.

Pregnancy and Lactation: The medicine is generally not recommended during pregnancy or while breastfeeding.

Required Caution: Use requires careful dose titration and clinical monitoring for patients who are elderly (over 65 years), those with a low body weight (leq 60 kg), or individuals with mild to moderate hepatic or renal impairment.

Interactions with other medicines and products

The way a medicine works in the body can be affected by other products taken at the same time. This is known as a drug-drug interaction. For Pelias, the majority of known interactions are related to how the drug is metabolized, or broken down, by specific liver enzymes and transporter proteins, primarily the Cytochrome P450 (CYP) 3A4 enzyme and the UGT1A1 pathway.

Co-administration with medicines that are strong inducers of CYP3A4 (substances that increase the activity of this enzyme) is officially restricted. This combination can significantly lower the concentration of Pelias in the blood, potentially compromising its intended effect. The concurrent use of these strong inducers is therefore avoided.

Conversely, when Pelias is taken with medicines identified as strong inhibitors of CYP3A4 or UGT1A1 (substances that slow the breakdown of Pelias), a risk of increased Pelias exposure exists. To manage this potential interaction, regulatory documents specify that a dose adjustment of Pelias is required. This procedural constraint ensures that the overall exposure remains within the safe and effective therapeutic range. Before starting or stopping any co-administered medicine, a full review of the current regimen is essential to determine if monitoring or a dosage change is necessary.

The active ingredients are Voltage-Gated Sodium Channel ( Na v) blockers that target the channels located on peripheral sensory nerve membranes. By binding to and obstructing the channel pore, the molecules impede the influx of sodium ions ( Na^+), which is essential for a nerve to generate an electrical impulse. This molecular interruption initiates the suppression of all electrical activity within the exposed nerve fibers.

This Na v blockade stops the rapid depolarization required for action potential propagation, resulting in a localized interruption of the nociceptive signal transduction pathway. This peripheral mechanism mediates the failure of sensory impulse transmission from the skin to the central nervous system, with the physiological consequence being a temporary suppression of sensory impulse conduction.

The formulation utilizes a complementary mechanism combining fast-acting Lidocaine with highly lipophilic Tetracaine. Lidocaine contributes to a rapid onset of the channel blockade, while Tetracaine’s physicochemical properties contribute to an extended tissue retention time, resulting in an extended duration and enhanced magnitude of the resulting nerve block. This synergy establishes a differentiated temporal profile for the peripheral nerve block.

How to Use Pelias (Ranolazine): Official Administration Guidelines

Pelias, which contains the active substance ranolazine, is an oral medication authorized for the continuous, long-term management of chronic stable angina. The standard administration protocol requires the drug to be taken twice daily (BID) to ensure stable drug exposure throughout the day. The typical starting dose is 500 mg twice daily. This initial dose may be titrated upwards, based on clinical response, to a maximum recommended dose of 1000 mg twice daily. It is important to note that certain dosing maximums differ between regions; for example, some European regimens prescribe a lower maintenance maximum.

The extended-release formulation necessitates specific administration constraints. The tablets must be swallowed whole and should not be crushed, broken, or chewed, as this action interferes with the drug’s sustained-release properties. The medication may be taken with or without food. If a dose is missed, the standard procedure is to take the next dose at the regular scheduled time; the next dose should never be doubled to compensate.

There are also specific conditions regarding dose modifications based on co-administration with other medicines. The maximum daily dose is strictly limited to 500 mg twice daily when Pelias is taken alongside moderate CYP3A inhibitors, such as diltiazem. This dose constraint is defined to mitigate potential changes in drug concentration. Furthermore, use is formally restricted in patients diagnosed with clinically significant hepatic impairment, defining a specific population where administration is not authorized.

Research evidence / Overview of Studies for Pelias (Ranolazine)

Evidence for Use in Chronic Stable Angina Pectoris

Research for Pelias was primarily conducted in the context of chronic stable angina pectoris, a condition that was the focus of the main research effort. This research involved multiple short-term (6 to 12 weeks), randomized, double-blind, placebo-controlled trials (RCTs). These studies were designed to monitor changes over periods typically ranging from 6 to 12 weeks. Additionally, large-scale, long-term cardiovascular outcomes trials provided data for stable angina patients with extended observation periods.

These controlled studies involved adult patients whose symptoms persisted even while they were taking other standard heart medicines. Research describes patterns measured in the studies related to outcomes reflecting daily functioning or activity level, as reported by the observed populations. Research describes changes measured during the study period for patients receiving Pelias relative to those receiving an inactive placebo.

Evidence from Functional and Symptom Studies

In the controlled trials, research examined changes in symptoms and physical ability. Patient-reported outcomes describing perceived discomfort were monitored, including how often patients experienced an angina episode and how frequently they needed to use acute symptom control medication (nitroglycerin). Studies explored changes in functional capacity by monitoring performance on standardized treadmill stress tests, which measured endpoints such as the time a patient could exercise. The data indicate patterns related to changes in patients' scores on these functional and symptom axes over the short-term study period.

Long-Term Research and Major Cardiovascular Outcomes

The research for Pelias over extended periods primarily consists of data from open-label studies that tracked long-term exposure. The core short-term RCTs focused on symptom and functional endpoints, but the follow-up durations were limited for establishing the sustained durability of patterns or assessing major health outcomes. Large cardiovascular outcomes trials examined major cardiovascular events, and findings for the study drug and control groups were not definitively distinct. Consequently, research contributing to understanding overall prognosis over many years remains insufficient, and long-term effects on major health outcomes are not fully established.

Common questions about Pelias (FAQ)

Q: Can Pelias be taken with food, or does it need to be taken on an empty stomach?

A: Regulatory guidelines state that Pelias may be taken either with food or without food. Official product information confirms that taking the medication with a meal does not affect how the drug is absorbed into the body.

Q: Is it true that Pelias can affect sleep?

A: Yes, official safety data indicates that Pelias can potentially affect sleep. Less common adverse reactions that have been reported in studies include both insomnia (difficulty sleeping) and somnolence (drowsiness or sleepiness).

Q: What are the most common reasons patients stop taking Pelias?

A: In clinical trials, patients most often stopped taking the medication due to common adverse reactions. These reactions, which include things like dizziness, nausea, and constipation, are the most frequent reasons documented for discontinuing the medication.

Q: What kind of studies were done to approve Pelias?

A: The drug's authorization was based on evidence from controlled clinical research, including multiple short-term, randomized, double-blind, placebo-controlled trials. These studies monitored changes in patient symptoms and functional capacity.

Q: What does the FDA label say about using Pelias during pregnancy?

A: Official labeling generally advises against using Pelias while pregnant. This guidance is in place because there is insufficient data from controlled studies to fully understand the effects on human pregnancy.

Q: Is it okay to use Pelias while breastfeeding?

A: The use of Pelias should be avoided while breastfeeding. Although it is not confirmed if the drug passes into human milk, animal studies have indicated its presence in animal milk.

Q: Are there different dosages of Pelias, and what are they for?

A: The medicine is available in 500 mg and 1000 mg strengths. Official guidelines define a standard starting strength and a maximum strength, with a lower maximum required for certain drug combinations. The strength prescribed depends on clinical considerations.

Q: What is the typical duration of treatment with Pelias?

A: Official documents state that Pelias is indicated for the continuous, long-term management of chronic stable angina. It is designed for ongoing treatment and should not be used to treat sudden or acute episodes of chest pain.

Q: Is Pelias for chronic conditions or acute episodes?

A: Pelias is an antianginal medicine specifically intended for the treatment of chronic stable angina. It is not indicated for treating acute, sudden episodes of chest pain.

Q: Are there any common foods or supplements that might interact with Pelias?

A: Yes, official product information advises against consuming grapefruit and grapefruit juice because they can increase the concentration of the drug in the blood. Concomitant use with the herbal supplement St. John’s wort is also restricted for similar reasons.

Q: Is Pelias considered a habit-forming or addictive drug?

A: No, according to regulatory classification, Pelias is not listed as a controlled substance under the Drug Enforcement Administration (DEA) scheduling system.

Q: If I take Pelias, can I still drive or operate heavy machinery?

A: The medication may cause side effects such as dizziness, lightheadedness, or syncope (fainting). Official sources state that because the drug may cause dizziness, individuals should assess their response to the medication before driving or operating complex machinery.

Q: Can men and women use Pelias for the same conditions?

A: Yes, Pelias is indicated for chronic stable angina in all adults. Official pharmacological studies have shown that the drug’s properties are not affected by a person’s sex.

Q: Does Pelias interact with birth control pills?

A: Regulatory documents describe interactions with liver enzymes that are responsible for breaking down many medications, including some oral contraceptives. Official documents specify that a review of all current medicines is essential to determine if monitoring or a dosage change is necessary when a patient starts or stops any co-administered medicine.

Q: Is it safe to drink alcohol while taking Pelias?

A: Official guidance suggests that consuming alcohol may increase the risk of certain side effects, such as dizziness. For some formulations of the medication, the regulatory guidance specifies that alcohol should be avoided entirely.

Q: Does my diet need to change while I'm on Pelias?

A: No general dietary changes are typically required during treatment with Pelias. However, consumption of grapefruit or grapefruit products is advised against because they can increase the concentration of the drug in the body.

Q: How long after stopping Pelias does it stay in your system?

A: The drug is eliminated from the body over time based on its apparent terminal half-life, which is approximately seven hours for the extended-release formulation. This characteristic determines the timeline for the drug to be fully cleared from the system.

Q: Is it possible to be allergic to the ingredients in Pelias?

A: Yes, regulatory documents list hypersensitivity (an allergic reaction) to ranolazine or any of the inactive ingredients as a contraindication. The drug is formally restricted (contraindicated) for use in patients with a known hypersensitivity or allergic reaction to any of its components.

Q: Is there long-term data available on the safety of Pelias?

A: Research includes data from long-term studies that monitored patients' exposure over extended periods. However, regulatory documents indicate that the effect of the medication on long-term major health outcomes is not fully established.

Q: What makes Pelias different from a placebo in clinical trials?

A: In controlled trials, the group receiving Pelias showed differences from the placebo group. These differences were documented as patterns related to changes in patient-reported symptoms and their performance on standardized exercise tests.

Q: Do you need to get special testing before starting Pelias?

A: Official guidance advises that patients be assessed for certain pre-existing conditions before use. Testing to assess liver and kidney function is part of the clinical evaluation process, as the drug is formally restricted in patients with severe impairment of these organs.

Q: Does Pelias require blood monitoring while taking it?

A: For most patients, routine blood monitoring is not required. However, for individuals who have pre-existing renal impairment or who are taking specific interacting medicines, blood monitoring of kidney function or drug concentration may be required.

Q: Can I take herbal supplements with Pelias?

A: Co-administration with the herbal supplement St. John’s wort is strictly restricted in regulatory documents. This is because St. John’s wort can significantly reduce the concentration of Pelias in the blood.

Q: Why is Pelias considered an important treatment option?

A: Pelias is authorized for use, often alongside other standard heart medicines, for the continuous treatment of chronic stable angina. It is considered when symptoms persist, establishing its role as an important addition to existing therapy.

Q: Does the time of day matter when taking Pelias?

A: The drug must be taken twice daily to maintain a stable drug concentration, meaning a dose should be taken approximately every 12 hours. Official documents do not specify a fixed time, such as morning or evening, for administration.

Q: What is the maximum recommended period for using Pelias?

A: Pelias is indicated for continuous, long-term management of the chronic condition. The official label does not specify a maximum duration of use that cannot be exceeded.

The storage and disposal of Pelias (ranolazine) must strictly follow the conditions specified in the official regulatory labeling.

Required Storage Conditions

Pelias must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from environmental factors by storing it away from excess heat, moisture, and direct light.

Container and Protection

It is mandatory to keep the medication in the original container it came in and ensure the container remains tightly closed. The labeling explicitly states that the product must be kept from freezing and stored out of the sight and reach of children.

Disposal

Patients should ask a healthcare professional or pharmacist how to dispose of any unused or expired tablets. Official documentation confirms that there are no special requirements for the disposal of the unused medicinal product as pharmaceutical waste.